ChartRow logo
Data provided bySource: Twelve Data
IMCR
$29.94-1.76%
as of close, Nov 13, 2026
☾ AH $29.94 -1.76%
Immunocore Holdings plc American Depositary SharesStock · HealthcareNasdaq Composite · 0.007% of ONEQ
PeersMRNALLYUNHMDTJNJTMO
Share this page

IMCR — Immunocore Holdings plc American Depositary Shares price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in IMCR be worth today? →
IMCR returns: By year · By month · By week · Trailing

Price data

Price
$29.94
YTD price return
-13.74%
YTD total return
-13.74%
Market cap
1.5B
Enterprise value
1.1B
Shares outstanding
51.7M
52W low
$27.50
52W high
$40.72
From 52W high
-26.46%
From 52W low
+8.87%
52W range
18%$27.50–$40.72

Volume

Rel volume
0.51×
30D volume
525.6K
30D $ vol
16M

Fundamentals

Sales (ttm)
429.3M
Sales/share
$8.31
EPS (ttm)
-$0.62
FCF (ttm)
-18.2M
FCF/share
-$0.35
Book value/share
$8.12
Net margin
-7.48%
ROE
-7.65%
ROA
-2.84%
Debt / equity
0.94×
Current ratio
4.62

Growth (CAGR, ttm) · 10Y

Sales
+13.11%+21.84%+68.08%n/a
Shares
+2.28%-1.55%+3.52%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+10.59%+20.23%+62.37%n/a
Book value/share
+3.48%+7.30%+9.50%n/a
Price
-15.36%-15.73%-5.43%n/a
Total return
-15.36%-15.73%-5.43%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-48.0×
Fwd P/E
-49.6×
P/S (ttm)
3.6×
P/B (mrq)
3.7×
EV/Sales (ttm)
2.5×
FCF yield (ttm)
-1.18%
Buyback yield (realized, 1y)
-2.28%
Shareholder yield (realized, 1y)
-2.28%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
4th
P/B
3rd

Bar = where today’s multiple sits in IMCR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
-1.76%
5D
-3.39%
1M
+7.62%
3M
-12.46%
YTD
-13.74%
1Y
-15.35%
5Y
-24.37%
1D
-1.76%
5D
-3.39%
1M
+7.62%
3M
-12.46%
YTD
-13.74%
1Y
-15.35%
5Y
-24.37%

Fundamentals#

Revenue

5Y CAGR +59.6%5Y CAGR +59.6%YoY −1.4%
$429.3M TTM$102.2M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$29M TTM−$13.6M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$0.62 TTM−$0.28 Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$18.2M TTM$17.7M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$10.4M, capex −$7.8M

Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $20.1M, capex −$2.3M

Shares (diluted)

5Y +89.8%5Y +89.8%YoY +2.3%
51.5M TTM51.6M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

5Y n/m5Y n/m
$0.00 FY25
FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full IMCR financials →

About Immunocore Holdings ADR#

Data provided bySource: Twelve Data

Immunocore Holdings plc ADR is a commercial-stage biotechnology company focused on developing T cell receptor-based immunotherapies designed to help the immune system recognize and eliminate diseased cells. Immunocore’s lead marketed product, KIMMTRAK, is used to treat unresectable or metastatic uveal melanoma, while its broader platform supports research and development across oncology, infectious diseases, and autoimmune disorders. The company’s ImmTAX technology underpins a portfolio of current and investigational therapies aimed at harnessing or redirecting immune responses with precision. Immunocore serves patients and healthcare providers through specialized therapies that address serious, hard-to-treat conditions, and its programs span clinical development as well as commercial operations in key international markets. Headquartered in Abingdon, United Kingdom, Immunocore Holdings plc ADR remains a notable participant in the biotechnology sector through its focus on novel immune-based medicines.

Abingdon, United Kingdom·497 employees·Biotechnology·immunocore.com·As of Oct 28, 2026

ETFs holding IMCR#

2 of the 193 ETFs ChartRow carries live hold IMCR. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF0.1%
ONEQFidelity Nasdaq Composite Index ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%